At the news
? BULLISHIMPACT 8/10 8-K filed Jul 29, 2026 at 07:06 ET
uniQure reported Q2 2026 results with a net loss of $1.22 per share, significantly missing the $-0.71 consensus estimate, while revenue of $5.8M slightly beat the $4.7M estimate. The headline miss is overshadowed by a transformative regulatory milestone: FDA alignment on an accelerated approval pathway for AMT-130 in Huntington's disease, with a BLA submission on track for Q3 2026. The company also strengthened its balance sheet with a $259M follow-on offering, extending the cash runway into 2030 and funding a potential commercial launch.
- FDA and uniQure reached alignment that a BLA submission under the accelerated approval pathway for AMT-130 is reasonable.
- BLA submission for AMT-130 on track for Q3 2026; topline four-year data expected in September 2026.
- Closed an upsized underwritten public offering of 5,686,813 shares at $45.50 per share for aggregate gross proceeds of $259 million.
- Cash, cash equivalents and current investment securities of $810.3 million as of June 30, 2026, sufficient to fund operations into 2030.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access